A phase II, multicenter, randomized, double-masked, 4 parallel arms, controlled 6-month trial designed to evaluate the safety and efficacy of PAD ciclosporin (CsA 0.06% and 0.03%) ophthalmic dispersion administered once daily in combination with lubricant therapy and a 3-month post-treatment safety follow-up in moderate to severe dry eye patients

Trial Profile

A phase II, multicenter, randomized, double-masked, 4 parallel arms, controlled 6-month trial designed to evaluate the safety and efficacy of PAD ciclosporin (CsA 0.06% and 0.03%) ophthalmic dispersion administered once daily in combination with lubricant therapy and a 3-month post-treatment safety follow-up in moderate to severe dry eye patients

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Nov 2017

At a glance

  • Drugs Ciclosporin (Primary)
  • Indications Dry eyes
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms NORTHERN LIGHTS
  • Sponsors MC2 Therapeutics
  • Most Recent Events

    • 09 Nov 2017 According to a MC2 Therapeutics media release, topline results are expected in 2018.
    • 09 Nov 2017 Status changed from recruiting to active, no longer recruiting, according to a MC2 Therapeutics media release.
    • 23 Mar 2017 This trial has been completed in Denmark.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top